Catalent enters AAV vector production agreement with IVERIC bio

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/krtiacanut)
(Image: Getty/krtiacanut)

Related tags: Viral vector, Production line, Clinical trial, Trial supply management, Clinical research, Catalent, Catalent pharma solutions

Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.

Iveric bio, which focuses on the development of gene therapy solutions for orphan inherited retinal diseases, will work with Catalent Biologics subsidiary, Paragon Gene Therapy.

Catalent acquired Paragon for $1.2bn in May 2019, for the production of preclinical and clinical trial supply of adeno-associated viral (AAV) vectors.

Together, the companies will produce the AAV vectors needed for Iveric’s drug therapy products IC-100 and IC-200 as they move into the clinic. Clinical trials for IC-100 are expected to begin in 2020 and 2021 for IC-200.

IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for the treatment of BEST1 related retinal diseases, which will be entering Phase I/II clinical trials within the next two years.

A spokesperson for Catalent Biologics told us that through this deal, Iveric bio will have access to Paragon’s manufacturing capabilities and capacity at Catalent’s site in Baltimore, Maryland.

No financial terms have been disclosed.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars